Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• CMS Grants New Technology Add-On Payment (NTAP) for PearlMatrix® P-15 Peptide Enhanced Bone Graft in Lumbar Fusion: Reported by OrthoSpineNews, Cerapedics announced that the Centers for Medicare & Medicaid Services (CMS) granted NTAP status under the FDA Breakthrough Devices pathway for PearlMatrix® P-15 Peptide Enhanced Bone Graft, providing supplemental reimbursement to hospitals for lumbar fusion.
• FDA CDRH Prioritizes Premarket Submission Guidance for Surgical Robotics and AI Lifecycle Management for FY2027: Reported by MedTech Dive, FDA CDRH released its FY2027 guidance priorities committing to finalize binding premarket submission requirements for robotically assisted surgical devices (RASD) alongside lifecycle management and Predetermined Change Control Plans (PCCPs) for AI-enabled software.
• Multinational Consensus Validates DISH Classification to Standardize Surgical Site Complication and Wound Healing Reporting: Reported by Healio Orthopedics, researchers from Oxford University Hospitals and the Johnson & Johnson Surgical Outcomes Program published a validated international Delphi consensus in the British Journal of Surgery establishing the DISH system to standardize postoperative wound complication reporting across orthopaedic specialties.
• Anika Therapeutics Integrity Retractable Implant Inserter Cleared: Anika Therapeutics, Inc. secured FDA 510(k) clearance (K261869) for the Integrity Retractable Implant Inserter (6000127), indicated for soft tissue fixation and rotator cuff tendon augmentation in sports medicine procedures.
• GS Medical The VEGA Cervical Screw System Cleared: GS Medical Co., Ltd. received FDA 510(k) clearance (K254260) for The VEGA Cervical Screw System, indicated for posterior occipital-cervical and upper thoracic arthrodesis fixation.

DAILY ANNOUNCEMENTS BY CATEGORY

Spine & Orthobiologics

Cerapedics, Inc. — CMS Grants New Technology Add-On Payment (NTAP) for PearlMatrix® P-15 Peptide Enhanced Bone Graft in Lumbar Fusion

• Summary: Cerapedics announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for PearlMatrix® P-15 Peptide Enhanced Bone Graft, effective October 1, 2026. Granted under CMS's alternative NTAP pathway reserved for FDA Breakthrough Devices, the designation provides substantial supplemental reimbursement to hospitals utilizing this Class III drug-device combination for skeletally mature patients undergoing lumbar fusion for degenerative disc disease.
• Key Details:
  • Device/System Name: PearlMatrix® P-15 Peptide Enhanced Bone Graft
  • Status: CMS New Technology Add-On Payment (NTAP) Approved (Effective October 1, 2026)
  • Clinical Significance: Lowers hospital financial adoption barriers for evidence-based bioactive bone grafting; P-15 synthetic peptide mimics the cell-binding domain of Type I collagen to facilitate native osteogenic cell attachment and osteoblast proliferation, accelerating lumbar interbody arthrodesis compared to standard bone graft substitutes.
• Original Source: OrthoSpineNews

Surgical Robotics, AI & Navigation

FDA Center for Devices and Radiological Health (CDRH) — FDA CDRH Prioritizes Premarket Submission Guidance for Surgical Robotics and AI Lifecycle Management for FY2027

• Summary: The U.S. FDA's Center for Devices and Radiological Health (CDRH) released its proposed A-list and B-list guidance priorities for the 2027 fiscal year, targeting finalization of two landmark digital surgery standards. CDRH committed to finalizing binding premarket submission guidance for robotically assisted surgical devices (RASD)—establishing unified nonclinical testing, clinical evidence benchmarks, and labeling requirements—alongside final guidance on lifecycle management and Predetermined Change Control Plans (PCCPs) for AI-enabled software.
• Key Details:
  • Device/System Name: Robotically Assisted Surgical Devices (RASD) & AI/ML Predetermined Change Control Guidance
  • Status: FDA CDRH FY2027 Regulatory Guidance Priority Publication
  • Clinical Significance: Provides long-awaited regulatory predictability for orthopaedic robotics, autonomous bone-cutting systems, and navigation platforms (including total knee, hip, and spine robotics), enabling medtech manufacturers to implement iterative machine learning software enhancements through pre-cleared PCCP protocols without triggering redundant 510(k) submissions.
• Original Source: MedTech Dive

Trauma & Extremities

Oxford University Hospitals / J&J Surgical Outcomes Program — Multinational Consensus Validates DISH Classification to Standardize Surgical Site Complication and Wound Healing Reporting

• Summary: Researchers from Oxford University Hospitals NHS Foundation Trust and the Johnson & Johnson Surgical Outcomes Program published a validated international classification system in the British Journal of Surgery to standardize surgical site outcome reporting. The DISH system evaluates dehiscence (D), inflammation/infection (I), seroma (S), and hematoma (H) through five objective grades of clinical intervention (0 through 4) and four grades of clinical presentation (a through d), developed via a four-round modified Delphi consensus spanning 14 surgical specialties across more than 30 countries.
• Key Details:
  • Device/System Name: DISH (Dehiscence, Inflammation/Infection, Seroma, Hematoma) Surgical Site Outcome Classification
  • Status: Peer-Reviewed Delphi Consensus Publication (British Journal of Surgery)
  • Clinical Significance: Creates an objective, standardized international nomenclature for tracking postoperative wound complications across orthopaedic trauma, arthroplasty, and spine surgery; enables reproducible multi-center benchmarking of surgical site infections, incisional complications, and the clinical efficacy of prophylactic wound dressings and negative pressure therapy.
• Original Source: Healio Orthopedics

RECENTLY INDEXED FDA 510(k) & PMA CLEARANCES — ORTHOPAEDIC

Note: The openFDA database typically indexes clearances 2–4 weeks after the official decision date. Dates shown reflect the FDA decision date, not the indexing date.